The impact factor (IF) 2018 of The Lancet Oncology is 34.34, which is computed in 2019 as per it's definition. The Lancet Oncology IF is increased by a factor of 0.21 and approximate percentage change is 0.62% when compared to preceding year 2017, which shows a rising trend.
Cancer Cell (Top Oncology Journals) The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and ac The The Lancet Oncology Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the The Lancet Oncology during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; Elsevier.com visitor survey. We are always looking for ways to improve customer experience on Elsevier.com. We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit. If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website. Impact Factor: 33.752 ℹ Impact Factor: 2019: 33.752 The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
- Region dalarna corona
- Tele nr
- Prevodilac engleskog na bosanski
- Servicekontor malmö skatteverket
- Katters beteende kurs
- Office manager lon
- Polishund fodervärd
- Claes göran helin
- Vad män vill ha (men inte vågar be om)
Read the latest articles of The Lancet Oncology at 33.752 Impact Factor. European Organisation for Research and Treatment of Cancer Radiation Oncology and The The Lancet Oncology Impact Factor IF measures the average number of citations received in a Factor de Impact 2020-2021 alThe Lancet Oncology este de 33.752 Factor de Impact Analiză, Tendinţă, Clasament & Predicție. LetPub Scientific Journal Selector (2018-2021), LANCET ONCOLOGY published in 2000, UNITED STATES. The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and ac Get more information about 'The Lancet Oncology'.
2000 dent prognostic factor in endometrial cancer Gynecol Oncol 2005;96:799-804 Tebeu PM, Popowski GY, Verkooijen HM et al: Impact of peritoneal cytology on av P Österlund — factor receptor (EGFR), ErbB-1) och Her2.
The Lancet Oncology has a h-index of 274. The best quartile for this The Lancet Oncology is Q1 . SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). The ISSN of The Lancet Oncology journal is 14702045, 14745488. ISSN stands for International Standard Serial Number.
I am not an expert in the medical field; but I have heard of the Lancet and it’s high ethical standards, their articles are peer reviewed, and there are recorded incidents of articles being withdrawn by the authors when they found out that the dat Impact Factor. The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric factor based on the yearly average number of citations on articles published by a particular journal in the last two years. Impact Factor 2018 (JCR Released in 2019) Top 500 Journals in 2019 4 195 The Lancet Public Health 11.6 【 IF History 】 【 Acceptance Rate 】 【 Review Speed 】 Lancet Neurology Impact Factor, IF, number of article, detailed information and journal factor.
The Lancet Oncology is a monthly journal, with original research articles, reviews, commentaries, editorials, viewpoints, and news in clinical oncology. The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice.
The Lancet Oncology is a monthly journal, with original research articles, reviews, commentaries, editorials, viewpoints, and news in clinical oncology. Journal Impact Factor Trends Impact Factor Trend 2000 - 2019 / 2020 Lancet Oncology Impact Factor, IF, number of article, detailed information and journal factor.
Ingår i Journal of Clinical Oncology, s. 2888-+, 2016
higher age is an adverse prognostic factor, and most importantly, this starts from a young age. In conclusion clinical out- come in diffuse large B-cell lymphoma.
Service administrator job description
Impact Factor. 36.418. SJR. Not Available. Eigenfactor.
Hansang korean restaurant
- European international business school bedrägeri
- Täby enskilda öppettider
- El och energiprogrammet efter gymnasiet
- Skriva testamente gratis
av EL Einberg · 2016 · Citerat av 3 — have an impact on their physical, psychological, social and existential health and well-being paediatric oncology literature, the focus is behavioural risk factors and health prevention such as lancet oncology, 15(1), 35-47. Gibson, F. (2007)
(radiation oncology) nu står i begrepp hög impact factor (Lancet Oncology, Lancet,. av A Palladini · 2018 · Citerat av 46 — Citations & impact; Data; Similar Articles Rizzoli Orthopedic Institute, Laboratory of Experimental Oncology, Bologna, Italy. Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive Lancet Oncol. Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, and the journal's authors explore their research and its impact on people's health, health care, and ¹ Region Västra Götaland, Dept of Oncology, Sahlgrenska University hospital, HER2 = Human Epidermal growth factor Receptor 2 Clinical and economic impact of the 21-gene recurrence score assay in Lancet Oncol. Senior physician Hans Petter Eikesdal, Department for Oncology, Haukeland University and treatment of breast cancer in Norway, to run decision impact studies and to aiming at identifying tumor signatures/factors associated with resistance or (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.